skip navigationU S P T O SealUnited States Patent and Trademark Office AOTW logo
Home|Site Index|Search|Guides|Contacts|eBusiness|eBiz alerts|News|Help
Assignments on the Web > Patent Query
Patent Assignment Assignee Details
NOTE:Results display only for issued patents and published applications. For pending or abandoned applications please consult USPTO staff.

Assignee Name : CVUS CLINICAL TRIALS, LLC
Total Assignments: 10
Assignment: 1
Reel/Frame:029494/0063   Pages: 12
Recorded: 12/18/2012
Attorney Dkt #:01682-35056.NP
Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).
Assignor
1
BIOTEX PHARMA INVESTMENTS LLC
Exec Dt:
06/26/2012
Assignee
1
CVUS CLINICAL TRIALS, LLC
350 AMERICAN PLAZA II 57 W. 200 S
SALT LAKE CITY, UTAH 84101
Property
 
Pat #
Pub #
Intl #
App #
 
 
 
 
 
 
 
 
 
 
 
8366617
US20080319318
12152631
Correspondence name and address
THORPE NORTH & WESTERN, LLP.
P.O. BOX 1219
SANDY, UT 84091-1219
Assignment: 2
Reel/Frame:045313/0562   Pages: 13
Recorded: 02/13/2018
Attorney Dkt #:QT_94T
Conveyance: CORRECTIVE ASSIGNMENT TO CORRECT THE EXECUTION DATE AND DOCUMENTATION PREVIOUSLY RECORDED ON REEL 042000 FRAME 0696. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT.
Assignor
1
BIOTEX PHARMA INVESTMENTS LLC
Exec Dt:
06/29/2012
Assignee
1
CVUS CLINICAL TRIALS, LLC
350 AMERICAN PLAZA II
SALT LAKE CITY, UTAH 84101
Property
 
Pat #
Pub #
Intl #
App #
 
 
 
 
 
 
 
 
 
 
 
7699783
US20060009696
11154006
Correspondence name and address
TALEM IP LAW, LLP
P.O. BOX 358880
GAINESVILLE, FL 32635
Assignment: 3
Reel/Frame:045314/0565   Pages: 13
Recorded: 02/13/2018
Attorney Dkt #:QT_95_CIP3_CON3T
Conveyance: CORRECTIVE ASSIGNMENT TO CORRECT THE EXECUTION DATE AND DOCUMENTATION PREVIOUSLY RECORDED ON REEL 042000 FRAME 0988. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT.
Assignor
1
BIOTEX PHARMA INVESTMENTS LLC
Exec Dt:
06/29/2012
Assignee
1
CVUS CLINICAL TRIALS, LLC
350 AMERICAN PLAZA II
SALT LAKE CITY, UTAH 84101
Property
 
Pat #
Pub #
Intl #
App #
 
 
 
 
 
 
 
 
 
 
 
7684846
US20070282200
11222541
Correspondence name and address
TALEM IP LAW, LLP
P.O. BOX 358880
GAINESVILLE, FL 32635
Assignment: 4
Reel/Frame:045974/0452   Pages: 13
Recorded: 03/27/2018
Attorney Dkt #:QT_93T
Conveyance: CORRECTIVE ASSIGNMENT TO CORRECT THE EXECUTION DATE AND DOCUMENTATION PREVIOUSLY RECORDED ON REEL 042000 FRAME 0493. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT.
Assignor
1
BIOTEX PHARMA INVESTMENTS LLC
Exec Dt:
06/29/2012
Assignee
1
CVUS CLINICAL TRIALS, LLC
350 AMERICAN PLAZA II
SALT LAKE CITY, UTAH 84101
Property
 
Pat #
Pub #
Intl #
App #
 
 
 
 
 
 
 
 
 
 
 
7771360
US20050143638
10821407
Correspondence name and address
TALEM IP LAW, LLP
P.O. BOX 358880
GAINESVILLE, FL 32635
Assignment: 5
Reel/Frame:040989/0820   Pages: 3
Recorded: 12/15/2016
Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).
Assignor
1
BIOTEX PHARMA INVESTMENTS, LLC
Exec Dt:
11/14/2016
Assignee
1
CVUS CLINICAL TRIALS, LLC
350 AMERICAN PLAZA II
57 W. 200 S.
SALT LAKE CITY, UTAH 84101
Property
 
Pat #
Pub #
Intl #
App #
 
 
 
 
 
 
 
 
 
 
 
8246543
US20080294043
12152637
Correspondence name and address
TALEM IP LAW, LLP
P.O. BOX 358880
GAINESVILLE, FL 32635-8880
Assignment: 6
Reel/Frame:042000/0493   Pages: 2
Recorded: 04/13/2017
Attorney Dkt #:QT_93T
Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).
Assignor
1
BIOTEX PHARMA INVESTMENTS, LLC
Exec Dt:
04/06/2017
Assignee
1
CVUS CLINICAL TRIALS, LLC
350 AMERICAN PLAZA II
57 W. 200 S.
SALT LAKE CITY, UTAH 84101
Property
 
Pat #
Pub #
Intl #
App #
 
 
 
 
 
 
 
 
 
 
 
7771360
US20050143638
10821407
Correspondence name and address
TALEM IP LAW, LLP
P.O. BOX 358880
GAINESVILLE, FL 32635
Assignment: 7
Reel/Frame:042000/0696   Pages: 2
Recorded: 04/13/2017
Attorney Dkt #:QT_94T
Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).
Assignor
1
BIOTEX PHARMA INVESTMENTS, LLC
Exec Dt:
04/06/2017
Assignee
1
CVUS CLINICAL TRIALS, LLC
350 AMERICAN PLAZA II
57 W. 200 S.
SALT LAKE CITY, UTAH 84101
Property
 
Pat #
Pub #
Intl #
App #
 
 
 
 
 
 
 
 
 
 
 
7699783
US20060009696
11154006
Correspondence name and address
TALEM IP LAW, LLP
P.O. BOX 358880
GAINESVILLE, FL 32635
Assignment: 8
Reel/Frame:042000/0988   Pages: 2
Recorded: 04/13/2017
Attorney Dkt #:QT_95_CIP3_CON3T
Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).
Assignor
1
BIOTEX PHARMA INVESTMENTS, LLC
Exec Dt:
04/06/2017
Assignee
1
CVUS CLINICAL TRIALS, LLC
350 AMERICAN PLAZA II
57 W. 200 S.
SALT LAKE CITY, UTAH 84101
Property
 
Pat #
Pub #
Intl #
App #
 
 
 
 
 
 
 
 
 
 
 
7684846
US20070282200
11222541
Correspondence name and address
TALEM IP LAW, LLP
P.O. BOX 358880
GAINESVILLE, FL 32635
Assignment: 9
Reel/Frame:042001/0186   Pages: 2
Recorded: 04/13/2017
Attorney Dkt #:QT_97T
Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).
Assignor
1
BIOTEX PHARMA INVESTMENTS, LLC
Exec Dt:
04/06/2017
Assignee
1
CVUS CLINICAL TRIALS, LLC
350 AMERICAN PLAZA II
57 W. 200 S.
SALT LAKE CITY, UTAH 84101
Property
 
Pat #
Pub #
Intl #
App #
 
 
 
 
 
 
 
 
 
 
 
8366617
US20080319318
12152631
Correspondence name and address
TALEM IP LAW, LLP
P.O. BOX 358880
GAINESVILLE, FL 32635
Assignment: 10
Reel/Frame:045788/0901   Pages: 3
Recorded: 02/13/2018
Attorney Dkt #:QT_97T
Conveyance: CORRECTIVE ASSIGNMENT TO CORRECT THE NATURE OF CONVEYANCE NUNC PRO TUNC ASSIGNMENT WITH EFFECTIVE DATE JULY 20, 2012 PREVIOUSLY RECORDED ON REEL 042001 FRAME 0186. ASSIGNOR(S) HEREBY CONFIRMS THE NUNC PRO TUNC ASSIGNMENT.
Assignor
1
BIOTEX PHARMA INVESTMENTS LLC
Exec Dt:
04/06/2017
Assignee
1
CVUS CLINICAL TRIALS, LLC
350 AMERICAN PLAZA II
SALT LAKE CITY, UTAH 84101
Property
 
Pat #
Pub #
Intl #
App #
 
 
 
 
 
 
 
 
 
 
 
8366617
US20080319318
12152631
Correspondence name and address
TALEM IP LAW, LLP
P.O. BOX 358880
GAINESVILLE, FL 32635

Search Results as of: 06/01/2024 06:42 PM
If you have any comments or questions concerning the data displayed, contact PRD / Assignments at 571-272-3350. v.2.6
Web interface last modified: August 25, 2017 v.2.6
| .HOME | INDEX| SEARCH | eBUSINESS | CONTACT US | PRIVACY STATEMENT